Johan Vekemans
20 Av Appia, 1211 Geneva 27
Appia, GE 1211, Switzerland
Appia, GE 1211, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 88 publications
Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate.
Journal: The New England journal of medicine
Published: November 05, 2025
Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans.
Journal: Science (New York, N.Y.)
Published: May 15, 2025
Effectiveness of the primary Bacillus Calmette-Guérin vaccine against the risk of Mycobacterium tuberculosis infection and tuberculosis disease: a meta-analysis of individual participant data.
Journal: The Lancet. Microbe
Published: May 17, 2024
Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults.
Journal: Human vaccines & immunotherapeutics
Published: March 21, 2024
What is next for BCG revaccination to prevent tuberculosis?
Journal: The Lancet. Respiratory medicine
Published: January 09, 2024
Measuring indirect transmission-reducing effects in tuberculosis vaccine efficacy trials: why and how?
Journal: The Lancet. Microbe
Published: February 14, 2023
An Aspiration to Radically Shorten Phase 3 Tuberculosis Vaccine Trials.
Journal: The Journal of infectious diseases
Published: February 01, 2023
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland.
Journal: The Lancet. Microbe
Published: January 31, 2023
Clinical trials of tuberculosis vaccines in the era of increased access to preventive antibiotic treatment.
Journal: The Lancet. Respiratory medicine
Published: November 16, 2022
A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India.
Journal: EClinicalMedicine
Published: August 19, 2021
Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial.
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: July 28, 2021
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.
Journal: Nature medicine
Published: June 21, 2021
Last Updated: 09/26/2026